Registry-listed formulations

Allopurinol sodium · chembl:CHEMBL1200477

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • ACEPURIN, poeder voor infusievloeistof 1g/100 mlRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Active Trials
0(0%)

Phase Distribution

Phase 3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Other(2)

Detailed Status

unknown2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

unknown2100%

Recent Activity

0 active trials
Showing 2 of 2
unknownphase_3

Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome

NCT03162653
unknownphase_3

Antenatal Allopurinol During Fetal Hypoxia

NCT00189007

Clinical Trials (2)

Showing 2 of 2 trials
NCT03162653Phase 3

Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome

Unknown
NCT00189007Phase 3

Antenatal Allopurinol During Fetal Hypoxia

Unknown

All 2 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
2

External References

ChEMBL
CHEMBL1200477

Names & Codes

Trade Names

aloprim

Research Codes

NSC-108836